dilTIAZem IV Bags Recalled Due to Lack of Sterilization Validation
Central Admixture Pharmacy Services is recalling 703 bags of dilTIAZem 125mg IV medication due to lack of validated sterilization processes. Healthcare providers and patients should verify lot numbers.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA classified this as a Class II drug recall. Although no illnesses or hospitalizations have been reported, the lack of validated sterilization for an intravenous medication represents a significant risk of harm to patients. This meets the rubric criterion for Score 3: risk-of-harm products where injury has not yet been reported.
Plain-English summary
Central Admixture Pharmacy Services, Inc. is recalling 703 bags of dilTIAZem 125mg/125mL IV solution added to dextrose 5% due to lack of assurance of sterility. The company failed to adequately validate the sanitization cycles used in manufacturing, raising concerns about whether the sterilization process effectively prevents microbial contamination.
The affected medication was distributed nationwide. Three lot numbers are involved: Lot 36-260048 (expiration 9/13/2023), Lot 36-262174 (expiration 9/15/2023), and Lot 36-262523 (expiration 9/19/2023). The product's NDC number is 72196-6054-1.
Healthcare providers should immediately check inventory to identify patients who may have received this medication from the affected lots. Patients and providers should consult with each other about whether additional monitoring is warranted. The FDA has classified this as a Class II recall, indicating the defect could potentially cause adverse health effects.
The recalled product
- Product
- dilTIAZem 125mg/125mL (1 mg/mL), added to dextrose 5%, IV Bag, RX only, Central Admixture Pharmacy Services, Inc., 2200 South 43rd Avenue, Phoenix, AZ 85043, NDC: 72196-6054-1
- Manufacturer
- Central Admixture Pharmacy Services, Inc.
- Category
- Drug — Intravenous Medication
- Affected units
- 703
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (6)
- Lot# 36-260048
- Exp 9/13/2023
- 36-262174
- Exp 9/15/2023
- 36-262523
- Exp 9/19/2023.
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 32 recalled by Central Admixture Pharmacy Services, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 32 products in this recall →Related recalls
Same manufacturer · Central Admixture Pharmacy Services, Inc.
See all →- ModeratePediatric TPN Bags Recalled for Incorrect Formulation
FDA (Drugs) · 2026-08-12
- SeverePediatric Total Parenteral Nutrition Bag Recalled for Incorrect Formulation
FDA (Drugs) · 2026-07-01
- SevereInjectable Phenylephrine Solution Recalled Due to Particulate Matter Contamination
FDA (Drugs) · 2025-03-19
- HighInjectable Lidocaine Recalled Due to Lack of Sterility Assurance
FDA (Drugs) · 2023-10-11
- HighMidazolam Injectable Solution Recalled Over Sterility Assurance Concerns
FDA (Drugs) · 2023-10-11
Same hazard · sterility assurance failure
See all →- HighDELFLEX Peritoneal Dialysis Solution bags recalled for sterility risk
FDA (Drugs) · 2026-05-13
- SevereTirzepatide/Cyanocobalamin Injectable Recalled Due to Sterility Assurance Failure
FDA (Drugs) · 2025-07-02
- HighOmnicell IVX Station Reconstitution Transfer Sets Recall
FDA (Devices) · 2025-04-16
- HighCompounded Fentanyl and Bupivacaine Epidural Injections Recalled for Sterility Assurance
FDA (Drugs) · 2025-04-02
- HighInjectable Phenylephrine Recall Due to Sterility Assurance Failure
FDA (Drugs) · 2024-04-03